Review
Copyright ©The Author(s) 2019.
World J Gastroenterol. Jan 14, 2019; 25(2): 163-177
Published online Jan 14, 2019. doi: 10.3748/wjg.v25.i2.163
Table 3 Novel therapeutic agents for non-alcoholic fatty liver disease/ non-alcoholic steatohepatitis under clinical trials
TargetAgentActionClinical trial
Diabetes, insulin resistanceSemaglutideDPP4 inhibitorPhase II
GliflozinSGLT2 inhibitor[89]Pilot
BMS-986036Recombinant FGF21[90]Phase II
DyslipidemiaAramcholSCD inhibitorPhase II
GS-0976ACC inhibitorPhase II
Nuclear receptorObeticholic acidFXR agonist[84]Phase III
ElafibranorPPARα/δ agonist[85]Phase III
MGL-3196TRβ agonistPhase II
ApoptosisEmricasanPan-caspase inhibitor[91]Phase II
Inflammation, fibrosisSelonsertibASK1 inhibitor[87]Phase III
CenicrivirocCCR2/5 antagonist[88]Phase III
JKB-121TLR4 antagonistPhase II
GR-MD-02Galectin 3 inhibitor[92]Phase II
ND-LO2-s0201HSP47 siRNA[93]Phase I